Brian M. Wolpin
Expertise in
9
conditions

Dr. Brian M. Wolpin

Oncology
Brigham and Women’s Hospital
Dana-Farber Brigham Cancer Center In Clinical Affiliation With South Shore Health
101 Columbian Street, South, 
South Weymouth, MA 
Offers Telehealth
Expertise in
9
conditions
Brigham and Women’s Hospital
Dana-Farber Brigham Cancer Center In Clinical Affiliation With South Shore Health
101 Columbian Street, South, 
South Weymouth, MA 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

Dr. Wolpin received his medical degree from Harvard Medical School in 2001. He subsequently completed his residency in Internal Medicine at Brigham and Women's Hospital, and his fellowship in Medical Oncology at the Dana-Farber Cancer Institute. He joined the staff of DFCI and Brigham and Women's Hospital in 2007, where he is a medical oncologist and clinical investigator in the Center for Gastrointestinal Oncology. His research focuses on biomarkers and novel therapeutics in gastrointestinal malignancies, and mechanisms by which lifestyle factors interact with malignant risk and progression.

Dr. Wolpin is highly rated in 9 conditions, according to our data. His top areas of expertise are Pancreatic Cancer, Pancreatic Ductal Adenocarcinoma, Colorectal Cancer, Pancreaticoduodenectomy, and Pancreatectomy.

His clinical research consists of co-authoring 244 peer reviewed articles and participating in 11 clinical trials. MediFind looks at clinical research from the past 15 years.

Graduate Institution
Harvard Medical School, 2001|Harvard School Of Public Health, 2008
Residency
Brigham and Women's Hospital, 2001 - 2004
Specialties
Oncology
Licenses
Internal Medicine in MA
Board Certifications
Medical Oncology
Fellowships
Dana Farber Cancer Institute******, 2004 - 2007
Hospital Affiliations
Brigham And Women's Hospital
Languages Spoken
English
Gender
Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Anthem
  • EPO
  • HMO
  • POS
  • PPO
Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
Cigna
  • EPO
  • HMO
  • PPO
Geisinger
  • HMO
  • POS
  • PPO
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Independent Health
  • EPO
  • POS
  • PPO
Managed Medicaid
  • OTHER MANAGED MEDICAID
Martin's Point Generations
  • MEDICARE MAPD
  • OTHER MEDICARE
Mass General Brigham Health Plan
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • PPO
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
Neighborhood
  • MANAGED MEDICAID PLAN
  • MEDICARE ASSISTANCE PROGRAM
  • MEDICARE-MEDICAID PLAN
  • OTHER COMMERCIAL
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 7 Less Insurance Carriers -

Locations

Dana-Farber Brigham Cancer Center in clinical affiliation with South Shore Health
101 Columbian Street, South, South Weymouth, MA 02190
Call: 617-632-6942
Other Locations
Dana-Farber Cancer Institute - Chestnut Hill
300 Boylston Street, Chestnut Hill, MA 02459
Call: 617-632-6942
Dana-Farber Cancer Institute, Center for Gastrointestinal Oncology
450 Brookline Avenue, Boston, MA 02115
Call: 617-632-6942

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

10 Clinical Trials

A Randomized Phase 2 Study of Losartan and Nivolumab in Combination With FOLFIRINOX and SBRT in Localized Pancreatic Cancer
A Randomized Phase 2 Study of Losartan and Nivolumab in Combination With FOLFIRINOX and SBRT in Localized Pancreatic Cancer
Enrollment Status: Active_not_recruiting
Publish Date: October 01, 2025
Intervention Type: Drug, Radiation, Procedure
Study Drugs: FOLFIRINOX, Losartan, Nivolumab
Study Phase: Phase 2
A Phase II Study of Niraparib and Dostarlimab With Radiation in Patients With Metastatic Pancreatic Cancer
A Phase II Study of Niraparib and Dostarlimab With Radiation in Patients With Metastatic Pancreatic Cancer
Enrollment Status: Completed
Publish Date: August 15, 2025
Intervention Type: Drug, Radiation
Study Drugs: Niraparib, Dostarlimab
Study Phase: Phase 2
Precision Promise Platform Trial for Metastatic Pancreatic Cancer
Precision Promise Platform Trial for Metastatic Pancreatic Cancer
Enrollment Status: Completed
Publish Date: April 06, 2025
Intervention Type: Drug
Study Drugs: Gemcitabine, Nab-paclitaxel, SM-88, mFOLFIRINOX
Study Phase: Phase 3
Phase II Trial of ERK Inhibition Alone and in Combination With Autophagy Inhibition in Patients With Metastatic Pancreatic Cancer
Phase II Trial of ERK Inhibition Alone and in Combination With Autophagy Inhibition in Patients With Metastatic Pancreatic Cancer
Enrollment Status: Completed
Publish Date: February 12, 2025
Intervention Type: Drug
Study Drugs: Hydroxychloroquine Sulfate, LY3214996
Study Phase: Phase 2
A Phase IIa, Multicenter, Open-label Study to Assess the Safety and Efficacy of the Combination of BL-8040 and Pembrolizumab in Patients With Metastatic Pancreatic Cancer, the COMBAT Study (KEYNOTE-202)
A Phase IIa, Multicenter, Open-label Study to Assess the Safety and Efficacy of the Combination of BL-8040 and Pembrolizumab in Patients With Metastatic Pancreatic Cancer, the COMBAT Study (KEYNOTE-202)
Enrollment Status: Completed
Publish Date: August 28, 2024
Intervention Type: Drug
Study Drugs: BL-8040, Pembrolizumab, Chemotherapy of Onivyde
Study Phase: Phase 2
BrafPanc: A Phase II Trial of Binimetinib in Combination With Encorafenib in Patients With Pancreatic Malignancies and a Somatic BRAFV600E Mutation
BrafPanc: A Phase II Trial of Binimetinib in Combination With Encorafenib in Patients With Pancreatic Malignancies and a Somatic BRAFV600E Mutation
Enrollment Status: Terminated
Publish Date: May 06, 2024
Intervention Type: Drug
Study Drugs: Binimetinib, Encorafenib
Study Phase: Phase 2
Nivolumab and Ipilimumab and Radiation Therapy in Metastatic, Microsatellite Stable Pancreatic Cancer
Nivolumab and Ipilimumab and Radiation Therapy in Metastatic, Microsatellite Stable Pancreatic Cancer
Enrollment Status: Active_not_recruiting
Publish Date: September 08, 2022
Intervention Type: Drug, Radiation
Study Drugs: Nivolumab, Ipilimumab
Study Phase: Phase 2
Preoperative Extended Chemotherapy vs. Chemotherapy Plus Hypofractionated Radiation Therapy for Borderline Resectable Adenocarcinoma of the Head of the Pancreas
Preoperative Extended Chemotherapy vs. Chemotherapy Plus Hypofractionated Radiation Therapy for Borderline Resectable Adenocarcinoma of the Head of the Pancreas
Enrollment Status: Unknown
Publish Date: May 24, 2022
Intervention Type: Drug, Procedure, Radiation
Study Drugs: mFOLFIRINOX, FOLFOX
Study Phase: Phase 2
A Phase I Dose Escalation Study, With Cohort Expansion, to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of AbGn-107 Therapy in Patients With Chemo-refractory Locally Advanced, Recurrent, or Metastatic Gastric, Colorectal, Pancreatic or Biliary Cancer
A Phase I Dose Escalation Study, With Cohort Expansion, to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of AbGn-107 Therapy in Patients With Chemo-refractory Locally Advanced, Recurrent, or Metastatic Gastric, Colorectal, Pancreatic or Biliary Cancer
Enrollment Status: Terminated
Publish Date: July 13, 2021
Intervention Type: Biological
Study Phase: Phase 1
A Single Arm Phase II Trial of Panitumumab in Cetuximab Refractory KRAS Wild-Type Colorectal Cancer
A Single Arm Phase II Trial of Panitumumab in Cetuximab Refractory KRAS Wild-Type Colorectal Cancer
Enrollment Status: Completed
Publish Date: May 16, 2017
Intervention Type: Drug
Study Phase: Phase 2
View 9 Less Clinical Trials

243 Total Publications

Erratum: PASS-01: Randomized Phase II Trial of Modified FOLFIRINOX Versus Gemcitabine/Nab-Paclitaxel and Molecular Correlatives for Previously Untreated Metastatic Pancreatic Cancer.
Erratum: PASS-01: Randomized Phase II Trial of Modified FOLFIRINOX Versus Gemcitabine/Nab-Paclitaxel and Molecular Correlatives for Previously Untreated Metastatic Pancreatic Cancer.
Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology
Published: September 24, 2025
View All 243 Publications
Similar Doctors
Expertise in
28
conditions
Dr. Jeremy S. Abramson
Oncology | Hematology
Expertise in
28
conditions
Dr. Jeremy S. Abramson
Oncology | Hematology

Massachusetts General Physicians Organization Inc

55 Fruit St, 
Boston, MA 
 (2.7 miles away)
617-724-0287
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Jeremy Abramson is an Oncologist and a Hematologist in Boston, Massachusetts. Dr. Abramson is highly rated in 28 conditions, according to our data. His top areas of expertise are Non-Hodgkin Lymphoma, B-Cell Lymphoma, Classical Hodgkin Lymphoma, Bone Marrow Transplant, and Tissue Biopsy. Dr. Abramson is currently accepting new patients.

Expertise in
25
conditions
Dr. Caron A. Jacobson
Oncology | Hematology | Hematology Oncology
Expertise in
25
conditions
Dr. Caron A. Jacobson
Oncology | Hematology | Hematology Oncology

Dana-Farber Cancer Institute, Inc.

450 Brookline Ave, 
Boston, MA 
 (0.1 miles away)
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Caron Jacobson is an Oncologist and a Hematologist in Boston, Massachusetts. Dr. Jacobson is highly rated in 25 conditions, according to our data. Her top areas of expertise are Non-Hodgkin Lymphoma, B-Cell Lymphoma, Follicular Lymphoma, Bone Marrow Transplant, and Bone Marrow Aspiration. Dr. Jacobson is currently accepting new patients.

Lori J. Wirth
Expertise in
24
conditions
Dr. Lori J. Wirth
Oncology
Expertise in
24
conditions
Dr. Lori J. Wirth
Oncology

The General Hospital Corporation

55 Fruit St, 
Boston, MA 
 (2.7 miles away)
617-726-2000
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Lori Wirth is an Oncologist in Boston, Massachusetts. Dr. Wirth is highly rated in 24 conditions, according to our data. Her top areas of expertise are Thyroid Cancer, Medullary Thyroid Carcinoma, Papillary Thyroid Cancer, Tissue Biopsy, and Thyroidectomy. Dr. Wirth is currently accepting new patients.

VIEW MORE Oncologists

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Wolpin's expertise for a condition
ConditionClose
  • Elite
  • Pancreatic Cancer
    Dr. Wolpin is
    Elite
    . Learn about Pancreatic Cancer.
    See more Pancreatic Cancer experts
  • Distinguished
  • Colorectal Cancer
    Dr. Wolpin is
    Distinguished
    . Learn about Colorectal Cancer.
    See more Colorectal Cancer experts
  • Familial Pancreatic Cancer
    Dr. Wolpin is
    Distinguished
    . Learn about Familial Pancreatic Cancer.
    See more Familial Pancreatic Cancer experts
  • Pancreatic Ductal Adenocarcinoma
    Dr. Wolpin is
    Distinguished
    . Learn about Pancreatic Ductal Adenocarcinoma.
    See more Pancreatic Ductal Adenocarcinoma experts
  • Advanced
  • Cholangiocarcinoma (Bile Duct Cancer)
    Dr. Wolpin is
    Advanced
    . Learn about Cholangiocarcinoma (Bile Duct Cancer).
    See more Cholangiocarcinoma (Bile Duct Cancer) experts
  • Familial Colorectal Cancer
    Dr. Wolpin is
    Advanced
    . Learn about Familial Colorectal Cancer.
    See more Familial Colorectal Cancer experts
  • Gastroenteropancreatic Neuroendocrine Tumor (GEP-NET)
    Dr. Wolpin is
    Advanced
    . Learn about Gastroenteropancreatic Neuroendocrine Tumor (GEP-NET).
    See more Gastroenteropancreatic Neuroendocrine Tumor (GEP-NET) experts
  • Neuroendocrine Tumor
    Dr. Wolpin is
    Advanced
    . Learn about Neuroendocrine Tumor.
    See more Neuroendocrine Tumor experts
  • Pancreatoblastoma
    Dr. Wolpin is
    Advanced
    . Learn about Pancreatoblastoma.
    See more Pancreatoblastoma experts
  • Experienced
  • Appendix Cancer
    Dr. Wolpin is
    Experienced
    . Learn about Appendix Cancer.
    See more Appendix Cancer experts
  • Carcinoid Syndrome
    Dr. Wolpin is
    Experienced
    . Learn about Carcinoid Syndrome.
    See more Carcinoid Syndrome experts
  • Esophageal Cancer
    Dr. Wolpin is
    Experienced
    . Learn about Esophageal Cancer.
    See more Esophageal Cancer experts
  • Gallbladder Adenocarcinoma
    Dr. Wolpin is
    Experienced
    . Learn about Gallbladder Adenocarcinoma.
    See more Gallbladder Adenocarcinoma experts
  • Gallbladder Cancer
    Dr. Wolpin is
    Experienced
    . Learn about Gallbladder Cancer.
    See more Gallbladder Cancer experts
  • Gallbladder Disease
    Dr. Wolpin is
    Experienced
    . Learn about Gallbladder Disease.
    See more Gallbladder Disease experts
View All 17 Experienced Conditions
Want to save this doctor for later?
Sign Up
Is this your doctor?
Find A Second Opinion
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile
  1. Homepage
  2. Oncologists South Weymouth, MA
  3. Dr. Brian M. Wolpin
For Patients
  • Our Story
  • How MediFind Works
  • Conditions A-Z
  • Doctor Directory
  • Symptoms Directory
  • Procedures Directory
  • Treatment Directory
  • Drug Directory
  • Infusion Center Finder
  • FAQ
  • Contact Us
For Providers and Practices
  • Claim Your Profile
  • Newsroom
Business Solutions
  • Provider
  • Network Solutions
Additional Resources
  • Consumer Health Data Privacy Policy
  • Privacy Policy
  • Terms of Use
  • Advertising Policy
  • Content Policy
Subscribe to our newsletter

Sign up to stay informed about MediFind and get wellness sent your way.

Close

    By subscribing, I agree to MediFind's Terms of Use, Privacy Policy and Consumer Health Data Privacy Policy, as applicable.

    Bullet PinMediFind
    Follow us on
    This information is not intended as a substitute for informed medical advice. You should work with a licensed professional to diagnose and treat health conditions. We let the data speak for itself, MediFind does not endorse any healthcare providers.
    © 2026 All Rights Reserved

    Request an Appointment

    If you are experiencing a medical emergency, call 9-1-1.

    MediFind will contact the provider for your appointment request. You’ll receive status updates by email. Your provider or MediFind will reach out to you directly by phone or email to schedule your appointment or request additional information.

    Patient Details

    This information is for the patient who will be seen at the appointment.

      Close

      Returning patient? Use your address on file with the provider.

      Insurance Details

      Please provide information of the primary insurance holder as the practice may require this information to schedule.

      Insurance Provider *
      Insurance ProviderClose

      Appointments Details

      Let’s get more information about your appointment.

              0 / 1000
              0 / 1000
              By pressing the Submit button you are agreeing to MediFind’s Terms of Use, Privacy Policy and Consumer Health Data Privacy Policy, as applicable.